✦ LIBER ✦

Phase II study of topotecan in metastatic hormone-refractory prostate cancer

✍ Scribed by Gary R. Hudes; Richard Kosierowski; Richard Greenberg; Harry E. Ramsey; Stephen C. Fox; Robert F. Ozols; Cecilia A. McAleer; Bruce J. Giantonio

Publisher: Springer US
Year: 1995
Tongue: English
Weight: 562 KB
Volume: 13
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00873806

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II evaluation of didemnin B in hor

Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer

✍ Stephen K. Williamson; Michael K. Wolf; Mario A. Eisenberger; Mark O'Rourke; Wil 📂 Article 📅 1995 🏛 Springer US 🌐 English ⚖ 302 KB

Phase II study of mitoxantrone and ketoc

Phase II study of mitoxantrone and ketoconazole for hormone-refractory prostate cancer

✍ John Eklund; Mark Kozloff; Joy Vlamakis; Alexander Starr; Margaret Mariott; Lili 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

The use of flutamide in hormone-refracto

The use of flutamide in hormone-refractory metastatic prostate cancer

✍ D. G. McLeod; R. C. Benson Jr; M. A. Eisenberger; E. D. Crawford; B. A. Blumenst 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 444 KB 👁 2 views

A phase I study of the somatostatin anal

A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer

✍ William D. Figg; Alain Thibault; Michael R. Cooper; Robert Reid; Donna Headlee; 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 578 KB

Oral estramustine and cyclophosphamide i

Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma : A phase II study

✍ Sergio Bracarda; Maurizio Tonato; Paolo Rosi; Verena De Angelis; Ettore Mearini; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

## BACKGROUND. Nearly all cases of metastatic prostate carcinoma progress, after hormonal ablation, to a hormone refractory status. To the authors' knowledge no standard chemotherapy for patients with hormone refractory prostate carcinoma (HRPC) exists. In a prospective study, the efficacy and toxi

A phase II study of recombinant human al

A phase II study of recombinant human alpha-interferon in advanced hormone-refractory prostate cancer

✍ Carol M. Van Haelst-Pisani; Ronald L. Richardson; John Su; Jan C. Buckner; Richa 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 306 KB 👁 2 views

To determine the efficacy of recombinant human leukocyte alpha-interferon (IFL-RA) in advanced hormone-refractory prostate cancer, the authors treated 40 patients with IFL-RA administered intramuscularly at a dose of 10 x 10' U/m2 three times weekly. Toxicity was substantial and necessitated at leas